Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
Retrieved on:
Sunday, October 30, 2022
Transplant, EAP, MESO, Inflammation, GLOBE, Director, Mesoblast, Chief, MACE, MSB, Private Securities Litigation Reform Act, GVHD, Company, BLA, FDA, Executive, Patient, Fast track (FDA), IND, Industry, Australian Securities Exchange, Death, Mostafa Rashidi Suja, Heart, ASX, Survival, SEC, Noriyuki Abe, Appendix, Policy, Investigational New Drug, LVEF, Pediatric Transplantation, Forward-looking statement, Pain, McMillan, Marketing, LVAD, Regenerative medicine, Hematopoietic stem cell transplantation, MOA, Risk, Immune system, Technology, Pharmaceutical industry, Birth control, Dietary supplement, Medical imaging, Management, Cryptocurrency
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022.
Key Points:
- NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022.
- The Company plans to have clearance from the FDA by year-end 2022 for the pivotal trial with primary endpoint 12-month reduction in pain.
- Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets.
- Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms.